NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mustang Bio, Inc. Common Stock (MBIO) Stock Analysis

Mustang Bio, Inc. Common Stock (MBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MBIO

$0.54

−$0.02 (−3.04%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBIO with… →

MBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$0.55
Previous Close
$0.56
Day's Range
0.53–0.56
52-Week Range
0.53–1.85
Volume
37.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.05
Valuation
Market Cap
$4.11M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.41
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.73M
1-Year Return
−63.06%
Dividend and dates
Avg Volume
41.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.65%
2025−88.92%
2024−86.89%
2023−77.22%
2022−76.20%
2021−56.14%
2020−7.23%
2019+38.78%
2018−75.48%
2017 (partial year)+22.35%

As of September 4, 2026.

MBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.92M—
2024$0.00−$15.75M—
2023$0.00−$51.60M—
2022$0.00−$77.53M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$2.43M−$1.92M—
2024$0.00—−$12.55M−$15.75M—
2023$0.00—−$50.73M−$51.60M—
2022$0.00—−$76.16M−$77.53M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricMBIOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Mustang Bio, Inc. Common Stock (MBIO) carries a market capitalisation of $4.11M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 4 employees.

The most recent close on file for MBIO is $0.54, dated September 4, 2026. That is −$0.02 (−3.04%) against the previous close. The 52-week range on file runs from $0.53 to $1.85. The latest close sits 3.43% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $1.92M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −0.41.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.05. Annualized volatility over the trailing 9 years is 199.28%. The trailing one-year price return is −63.06%. Across 5 years the annualized return works out at −81.07%.

Growth & Income

The record shows no dividend for MBIO.

Across the complete calendar years on file, 2019 returned +38.78% and 2025 returned −88.92%. Of the 8 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −44.65% year to date.

Peer Comparison

Mustang Bio, Inc. Common Stock (MBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mustang Bio, Inc. Common Stock MBIO $4.11M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mustang Bio, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mustang Bio, Inc. Common Stock

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Visit website →